Transverse myelitis after Johnson & Johnson COVID-19 vaccine: illustrative case.
Johnson & Johnson COVID-19 vaccine
rapid corticosteroid initiation
transverse myelitis
Journal
Journal of neurosurgery. Case lessons
ISSN: 2694-1902
Titre abrégé: J Neurosurg Case Lessons
Pays: United States
ID NLM: 9918227275606676
Informations de publication
Date de publication:
12 Dec 2022
12 Dec 2022
Historique:
received:
31
05
2022
accepted:
12
08
2022
entrez:
22
1
2023
pubmed:
23
1
2023
medline:
23
1
2023
Statut:
epublish
Résumé
Transverse myelitis is a rare neurological occurrence with varied presentation. Imaging is necessary to properly diagnose this condition; however, identifying the cause of this condition may often be difficult. An otherwise healthy patient presented to the clinic with peculiar neurological symptoms without an obvious underlying cause. Imaging evidenced no significant structural defects but did lead to discovery of cord enhancement compatible with a diagnosis of transverse myelitis. Corticosteroid treatment was initiated rapidly to address this pathology, and the patient recovered without deficits. To identify the underlying cause, patient medical history was reviewed thoroughly and compared with existing literature. Previous tuberculosis infection could be a less likely cause of the neurological symptoms. However, recent vaccination with the Johnson & Johnson coronavirus disease 2019 (COVID-19) vaccine could be a more likely cause of the transverse myelitis, which has been rarely reported. Transverse myelitis after COVID-19 infection has been an escalating phenomenon. However, transverse myelitis after COVID-19 vaccination is a rare occurrence that is also on the rise. Given the increased rates of vaccination, transverse myelitis should not be overlooked as a potential pathology, due to the severity of neurological impairment if this condition is not treated rapidly.
Sections du résumé
BACKGROUND
BACKGROUND
Transverse myelitis is a rare neurological occurrence with varied presentation. Imaging is necessary to properly diagnose this condition; however, identifying the cause of this condition may often be difficult.
OBSERVATIONS
METHODS
An otherwise healthy patient presented to the clinic with peculiar neurological symptoms without an obvious underlying cause. Imaging evidenced no significant structural defects but did lead to discovery of cord enhancement compatible with a diagnosis of transverse myelitis. Corticosteroid treatment was initiated rapidly to address this pathology, and the patient recovered without deficits. To identify the underlying cause, patient medical history was reviewed thoroughly and compared with existing literature. Previous tuberculosis infection could be a less likely cause of the neurological symptoms. However, recent vaccination with the Johnson & Johnson coronavirus disease 2019 (COVID-19) vaccine could be a more likely cause of the transverse myelitis, which has been rarely reported.
LESSONS
CONCLUSIONS
Transverse myelitis after COVID-19 infection has been an escalating phenomenon. However, transverse myelitis after COVID-19 vaccination is a rare occurrence that is also on the rise. Given the increased rates of vaccination, transverse myelitis should not be overlooked as a potential pathology, due to the severity of neurological impairment if this condition is not treated rapidly.
Identifiants
pubmed: 36681970
doi: 10.3171/CASE22244
pii: CASE22244
pmc: PMC9745584
doi:
pii:
Types de publication
Journal Article
Langues
eng
Références
Spinal Cord Ser Cases. 2021 Sep 14;7(1):82
pubmed: 34521808
Nat Med. 2021 Dec;27(12):2144-2153
pubmed: 34697502
IDCases. 2019 May 24;17:e00564
pubmed: 31193733
Arch Neurol. 1963 Aug;9:111-9
pubmed: 14048158
Curr Opin Neurol. 2006 Aug;19(4):362-8
pubmed: 16914974
Ann Med Surg (Lond). 2021 Sep;69:102749
pubmed: 34457267
Front Immunol. 2021 Apr 26;12:653786
pubmed: 33981305
Semin Neurol. 2012 Apr;32(2):97-113
pubmed: 22961185
Cureus. 2021 Jul 25;13(7):e16624
pubmed: 34458035
Cureus. 2021 Sep 2;13(9):e17658
pubmed: 34650845
J Postgrad Med. 2014 Oct-Dec;60(4):409-12
pubmed: 25370554
Vaccines (Basel). 2021 Sep 10;9(9):
pubmed: 34579245
Ann Med Surg (Lond). 2021 Sep;69:102709
pubmed: 34405043
J Neurol. 2022 Mar;269(3):1121-1132
pubmed: 34482455
Springerplus. 2015 Sep 04;4:476
pubmed: 26361577
Discov Med. 2013 Oct;16(88):167-77
pubmed: 24099672
J Neurovirol. 2021 Apr;27(2):354-358
pubmed: 33650074
Curr Neurol Neurosci Rep. 2006 May;6(3):236-43
pubmed: 16635433
Lupus. 2009 Nov;18(13):1198-204
pubmed: 19880568
Neurology. 2002 Aug 27;59(4):499-505
pubmed: 12236201
QJM. 2021 Nov 5;114(8):591-593
pubmed: 33787891
J Neurovirol. 2021 Oct;27(5):791-796
pubmed: 34449062